Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
NASAREL vs NASALIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.
Corticosteroid that reduces inflammation by inhibiting phospholipase A2, decreasing arachidonic acid release, and suppressing prostaglandin and leukotriene synthesis.
Seasonal and perennial allergic rhinitis,Nonallergic rhinitis,Nasal polyps (off-label)
FDA: Management of seasonal or perennial allergic rhinitis symptoms,Off-label: Nonallergic rhinitis, nasal polyps
2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.
2 sprays (100 mcg total) per nostril twice daily; maximum 8 sprays (400 mcg) per day in each nostril.
Terminal half-life approximately 15-25 minutes for flunisolide (the active ingredient in NASAREL) in the systemic circulation after intranasal administration. Clinically, the half-life is short, reducing the risk of systemic accumulation but requiring twice-daily dosing for consistent effect.
Terminal elimination half-life: 1-2 hours; clinically, intranasal dosing achieves prolonged local effects with minimal systemic accumulation.
Primarily hepatic via CYP3A4 isoform; undergoes extensive first-pass metabolism.
Primarily hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Primarily hepatic metabolism; renal excretion of metabolites accounts for <30% of dose. Fecal elimination minimal (<5%).
Primarily hepatic metabolism via CYP3A4; metabolites and unchanged drug excreted in feces (approximately 60%) and urine (approximately 40%, with <1% unchanged).
Approximately 40-50% bound to plasma proteins, primarily albumin.
High (approximately 80%), primarily bound to albumin.
Volume of distribution is approximately 1.4–2.0 L/kg after IV administration, indicating extensive tissue distribution. For intranasal use, the Vd is not directly applicable but reflects systemic exposure if absorbed.
Approximately 2.8 L/kg; indicates extensive tissue distribution.
Intranasal: Systemic bioavailability is approximately 21% (range 10-50%) due to first-pass metabolism. Oral bioavailability is <1% due to extensive hepatic first-pass effect. The drug is administered intranasally for local effect with low systemic exposure.
Intranasal: Approximately 49% systemic absorption relative to intravenous administration; oral bioavailability <1% due to extensive first-pass metabolism.
No dose adjustment required for renal impairment.
No dosage adjustment required for renal impairment.
No dose adjustment required for hepatic impairment.
No specific guidelines; use with caution in severe hepatic impairment due to potential corticosteroid effects.
Children 6-11 years: 1 spray in each nostril once daily; maximum 4 sprays/day. Children ≥12 years: same as adult.
Children 6-14 years: 1 spray (50 mcg) per nostril twice daily; maximum 4 sprays (200 mcg) per day in each nostril. Children ≥14 years: same as adult.
No specific dose adjustment; use lowest effective dose.
No specific adjustment; use lowest effective dose due to potential increased osteoporosis risk.
None
None.
May cause epistaxis, nasal septal perforation, or nasal mucosal ulceration,Potential for systemic corticosteroid effects with prolonged use,May suppress hypothalamic-pituitary-adrenal (HPA) axis, especially at higher doses,Increased susceptibility to infections; avoid in active untreated infections,Use with caution in patients with tuberculosis, ocular herpes simplex, or untreated fungal/bacterial infections
May cause growth suppression in children with prolonged use,Potential for adrenal insufficiency with systemic absorption,Nasal septum perforation and local irritation reported,Monitor for immunosuppression or infections (e.g., Candida)
Hypersensitivity to flunisolide or any component of the formulation,Untreated localized nasal infections (e.g., bacterial, fungal, viral)
Hypersensitivity to flunisolide or any component,Untreated localized nasal mucosal infections (e.g., herpes simplex)
No significant food interactions known. May take without regard to meals. Avoid consuming grapefruit or grapefruit juice as it may increase systemic exposure (weak CYP3A4 interaction).
No specific food interactions reported. However, avoid grapefruit and grapefruit juice as they may increase systemic absorption via CYP3A4 inhibition, though topical corticosteroids have minimal systemic bioavailability.
FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (flunisolide) should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. First trimester: Theoretical risk of cleft palate; avoid systemic absorption by using minimal effective dose. Second and third trimesters: No specific risks reported; monitor for fetal adrenal suppression if used chronically at high doses.
FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at high systemic doses. However, intranasal flunisolide has minimal systemic absorption; therefore, fetal exposure is low. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if potential benefit justifies potential risk to the fetus. First trimester: insufficient data; avoid unless necessary. Second and third trimesters: no specific risks identified; limited data suggest safety.
It is not known whether flunisolide is excreted in human milk. Because many corticosteroids are excreted in human milk, caution should be exercised when Nasarel is administered to a nursing woman. M/P ratio not available. Use with caution; consider using lowest effective dose and monitoring infant for signs of adrenal suppression.
It is not known whether flunisolide is excreted in human breast milk. Because many corticosteroids are excreted in human milk, caution should be exercised when intranasal flunisolide is administered to a nursing woman. M/P ratio: not available.
No specific dose adjustments required due to pharmacokinetic changes in pregnancy. Use lowest effective dose to minimize systemic absorption. No change in hepatic metabolism or renal clearance expected for intranasal flunisolide.
No dose adjustment required. Pharmacokinetic changes during pregnancy (increased volume of distribution and clearance) may affect systemic corticosteroids but intranasal flunisolide undergoes minimal systemic absorption; clinical pharmacokinetic data during pregnancy are lacking. Use the lowest effective dose for the shortest duration.
For best results, advise patients to blow nose gently before use. Avoid spraying directly onto nasal septum to reduce risk of epistaxis and septal perforation. Tilt head forward slightly and spray away from septum. Priming pump (6 sprays or until fine mist appears) is essential if not used for >7 days. Monitor nasal mucosal integrity during long-term use. May cause transient stinging or burning; consider co-administration with saline spray if irritation persists.
NASALIDE (flunisolide) is a corticosteroid nasal spray for allergic rhinitis. Titrate to lowest effective dose to minimize systemic absorption. Advise patients to clear nasal passages before use. Monitor for nasal irritation, epistaxis, or rarely, septal perforation. Not for acute symptom relief; onset of action may take several days.
Use exactly as prescribed; do not exceed recommended dose.,Shake bottle gently before each use.,Prime pump by spraying 6 times into air if new or not used for 7 or more days.,Blow nose to clear nasal passages before administration.,Insert nozzle into nostril, tilt head slightly forward, and spray away from the nasal septum.,Avoid spraying directly onto the nasal septum.,Rinse nozzle with warm water after each use and replace cap tightly.,Do not share the medication with others.,If using other nasal sprays, use them at different times (separated by 10-15 minutes).,Contact doctor if symptoms do not improve after 3 weeks or if nasal bleeding occurs.
Use regularly for best results; do not expect immediate relief.,Shake bottle gently before each use.,Prime the pump by spraying into the air 5-6 times before first use or if not used for 2 weeks.,Blow nose gently before spraying to clear nasal passages.,Insert nozzle into nostril, aim away from the septum, and spray while breathing in.,Avoid spraying into eyes; if contact occurs, rinse with water.,Rinse nozzle with warm water after each use to prevent clogging.,Do not exceed recommended dosage; overuse can lead to systemic side effects.,Contact doctor if symptoms worsen or persist after 3 weeks.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about NASAREL vs NASALIDE, answered by our medical review team.
NASAREL is a Intranasal Corticosteroid that works by Corticosteroid that binds to glucocorticoid receptors, inhibiting inflammatory mediators such as prostaglandins, leukotrienes, and cytokines, thereby reducing nasal inflammation.. NASALIDE is a Intranasal Corticosteroid that works by Corticosteroid that reduces inflammation by inhibiting phospholipase A2, decreasing arachidonic acid release, and suppressing prostaglandin and leukotriene synthesis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between NASAREL and NASALIDE depend on the specific clinical indication. These are both Intranasal Corticosteroid agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of NASAREL is: 2 sprays (50 mcg/spray) in each nostril once or twice daily; maximum 8 sprays/day.. The standard adult dose of NASALIDE is: 2 sprays (100 mcg total) per nostril twice daily; maximum 8 sprays (400 mcg) per day in each nostril.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between NASAREL and NASALIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. NASAREL is classified as Category C. FDA Pregnancy Category C: In animal studies, corticosteroids have been shown to be teratogenic at high doses. No adequate and well-controlled studies in pregnant women. Nasarel (fl. NASALIDE is classified as Category C. FDA Pregnancy Category C. In animal studies, corticosteroids have been shown to be teratogenic at high systemic doses. However, intranasal flunisolide has minimal systemic absorpti. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.